| Literature DB >> 27698953 |
Carla Busquets-Cortés1, Xavier Capó1, Miquel Martorell2, Josep A Tur3, Antoni Sureda3, Antoni Pons3.
Abstract
Exercise training induces adaptations in mitochondrial metabolism, dynamics, and oxidative protection. Omega-3 fatty acids change membrane lipid composition and modulate mitochondrial function. The aim was to investigate the effect of 8-week training and docosahexaenoic acid (DHA) supplementation (1.14 g/day) on the mitochondria dynamics and antioxidant status in peripheral blood mononuclear cells (PBMCs) from sportsmen. Subjects were assigned to an intervention (N = 9) or placebo groups (N = 7) in a randomized double-blind trial. Nutritional intervention significantly increased the DHA content in erythrocyte membranes from the experimental group. No significant differences were reported in terms of circulating PBMCs, Mn-superoxide dismutase protein levels, and their capability to produce reactive oxygen species. The proteins related to mitochondrial dynamics were, in general, increased after an 8-week training and this increase was enhanced by DHA supplementation. The content in mitofusins Mtf-1 and Mtf-2, optic atrophy protein-1 (Opa-1), and mitochondrial transcription factor A (Tfam) were significantly higher in the DHA-supplemented group after intervention. Cytochrome c oxidase (COX-IV) activity and uncoupling proteins UCP-2 and UCP-3 protein levels were increased after training, with higher UCP-3 levels in the supplemented group. In conclusion, training induced mitochondrial adaptations which may contribute to improved mitochondrial function. This mitochondrial response was modulated by DHA supplementation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27698953 PMCID: PMC5028859 DOI: 10.1155/2016/8950384
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Effects of training and DHA supplementation on PBMC counts.
| Initial | Final | ANOVA | ||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| PBMCs (103 cells/ | Placebo | 2.47 ± 0.6 | 2.98 ± 0.4 | |||
| Experimental | 2.92 ± 0.2 | 3.61 ± 3.6 | ||||
|
| ||||||
| Lymphocytes (%) | Placebo | 79.9 ± 6.6 | 82.9 ± 4.3 | |||
| Experimental | 85.1 ± 2.9 | 85.3 ± 3.6 | ||||
|
| ||||||
| Monocytes (%) | Placebo | 20.1 ± 5.5 | 17.0 ± 3.8 | |||
| Experimental | 14.9 ± 3.9 | 14.7 ± 3.3 | ||||
Statistical analysis: two-way ANOVA, p < 0.05. (T) significant effect of time of training, (S) significant effect of supplementation, (S × T) significant interaction between both factors. No significant differences were reported.
Figure 1Effects of training and DHA supplementation on ROS production by PBMCs after PMA stimuli. Statistical analysis: two-way ANOVA, p < 0.05. No significant differences were reported.
Oxidative damage in PBMCs.
| Initial | Final | ANOVA | ||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Malondialdehyde | Placebo | 440 ± 70 | 160 ± 10# | X | ||
| Experimental | 510 ± 70 | 330 ± 40# | ||||
|
| ||||||
| Protein Carbonyls (%) | Placebo | 100 ± 30 | 838 ± 78# | X | ||
| Experimental | 94 ± 22 | 792 ± 65# | ||||
Statistical analysis: two-way ANOVA, p < 0.05. (T) significant effect of training period, (S) significant effect of supplementation, (S × T) significant interaction between both factors. One-way ANOVA, p < 0.05. #: significant differences between initial and final training period.
Figure 2Effects of training and DHA supplementation on mitochondrial protein levels of PBMCs. (a) uncoupling protein- (UCP-) 2, (b) UCP-3, (c) Mn-superoxide dismutase (Mn-SOD), and (d) cytochrome c oxidase (COXIV). Statistical analysis: two-way ANOVA, p < 0.05. T, significant effect of training; S, significant effect of DHA supplementation. One-way ANOVA, p < 0.05. (∗) Significant differences between placebo and experimental groups; (#) significant differences between initial and final training period.
Effects of training and DHA supplementation on mitochondrial dynamics protein levels of PBMCs.
| Initial | Final | ANOVA | ||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| PGC-1 | Placebo | 100 ± 15 | 152 ± 22 | X | ||
| Experimental | 65.3 ± 5.9 | 152 ± 29# | ||||
|
| ||||||
| NRF-1 (%) | Placebo | 100 ± 19 | 148 ± 9 | X | ||
| Experimental | 59.5 ± 14.7 | 158 ± 23# | ||||
|
| ||||||
| Tfam (%) | Placebo | 100 ± 14a | 154 ± 24b | X | X | |
| Experimental | 78.8 ± 23.7a | 231 ± 15c | ||||
|
| ||||||
| Mfn-1 (%) | Placebo | 100 ± 22a | 129 ± 15a | X | X | X |
| Experimental | 92.6 ± 17a | 250 ± 26b | ||||
|
| ||||||
| Mfn-2 (%) | Placebo | 100 ± 19a | 98.9 ± 11.9a | X | X | X |
| Experimental | 108 ± 33a | 203 ± 29b | ||||
|
| ||||||
| OPA-1 (%) | Placebo | 100 ± 23 | 217 ± 84# | X | ||
| Experimental | 134 ± 19 | 218 ± 25# | ||||
|
| ||||||
| OMA-1 (%) | Placebo | 100 ± 11a | 163 ± 25b | X | X | |
| Experimental | 64.8 ± 13.7a | 219 ± 17c | ||||
|
| ||||||
| FIS-1 (%) | Placebo | 100 ± 15 | 88.0 ± 27.4 | |||
| Experimental | 115 ± 16 | 125 ± 16 | ||||
Statistical analysis: two-way ANOVA, p < 0.05. (T) significant effect of time of training, (S) significant effect of supplementation, (S × T) significant interaction between both factors. One-way ANOVA, p < 0.05. (∗) significant differences between placebo and experimental, (#) significant differences between initial and final training period. When interaction exists between different groups, distinct letters (a, b, and c) reveal significant differences with respect to all other groups.
Figure 3Representative picture of the bands obtained by immunoblotting.